---
title: "HELP: HLP003 and HLP004 show strong Phase 2 efficacy and safety, advancing toward pivotal trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291142706.md"
description: "Two proprietary programs, HLP003 for MDD and HLP004 for GAD, have shown rapid, durable efficacy and favorable safety in Phase 2 trials, with HLP003 in Phase 3 and strong patent protection through 2041. The company is well-funded and positioned to address large unmet needs in mental health.Original document: Cybin, Inc. [HELP] Slides Release — Jun. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-29T12:03:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291142706.md)
  - [en](https://longbridge.com/en/news/291142706.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291142706.md)
generator: "portal-rs"
---

# HELP: HLP003 and HLP004 show strong Phase 2 efficacy and safety, advancing toward pivotal trials

Two proprietary programs, HLP003 for MDD and HLP004 for GAD, have shown rapid, durable efficacy and favorable safety in Phase 2 trials, with HLP003 in Phase 3 and strong patent protection through 2041. The company is well-funded and positioned to address large unmet needs in mental health.

Original document: Cybin, Inc. \[HELP\] Slides Release — Jun. 29 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [Cybin announces annual general and special shareholder meeting](https://longbridge.com/en/news/296336431.md)
- [Cybin publishes corporate presentation on development of serotonergic agonists for depression, anxiety](https://longbridge.com/en/news/294701596.md)
- [Consulting's race to become AI native](https://longbridge.com/en/news/296676838.md)
- [Protagenic gets FDA pre-IND feedback supporting planned Phase 1 trial for PT00114 in generalized anxiety disorder](https://longbridge.com/en/news/296491293.md)
- [SoftBank CISO Iida says sovereign AI push aims to keep customer data within Japan](https://longbridge.com/en/news/296442282.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**